Theme 2 Flashcards

1
Q

Link reaction

  • where
  • enzyme
  • reaction type
A

Matrix
Pyruvate dehydrogenase
Oxidative decarboxylation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Committed step enzyme

A

PFK-1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

SLP enzymes

A

Hk and PFK-1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

TCA products

A

3NADH, 1 FADH2, GTP, 2CO2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Inner membrane impermeable to

A

NADH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Coenzymes [5]

A

NAD, Biotin, TPP, CoA, Lipoic acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Riboflavin

A

B2

FAD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Thiamine

A

B1

TPP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Niacin

A

NADP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Pantothenate

A

B5

CoA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

FAD

A

Riboflavin

B2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

CoA

A

Pantothenate

B5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

TPP

A

Thiamine

B1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

NADP

A

Niacin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

ROS [5]

A
Superoxide anion 
Hydroxyl radical 
Hydrogen peroxide 
Peroxide ion 
Hypochlorous acid
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Mt disease overview

A

150 diff types
16.5kb
5-10 copies
900 diff mt proteins

13 resp chain proteins, 2 rRNA and 22 tRNA

17
Q

Mt myopathies

A
1. Defects of mitochondrial transport systems
Carnitine palmitoyltransferase (CPT I and II) deficiencies
  1. Defects of substrate utilisation
    Pyruvate dehydrogenase complex (PDC) deficiency
    Fatty acid oxidation defects
  2. Defects of TCA cycle
    Fumarase deficiency OR - ketoglutarate dehydrogenase deficiency
  3. Defects of OXPHOS coupling
    Luft’s syndrome
  4. Defects of oxidative phosphorylation
    Complexes I / II / III / IV / V deficiencies combined defects of respiratory chain components
18
Q

In LHON, electron transport from what is insufficient

A

Succinate

19
Q

MERF

A

TK, TL1, TH, TF
Oxidative phosphorylation
Point mutation - tRNA for tyrosine

20
Q

MELAS

A

ND5

TH, TL1, TF

21
Q

KSS

A

5kb deletion
short stature, multiple endocrinopathies
Lactic acidosis, heart conduction defect and CSF protein content

22
Q

Normal glucose concentration

A

2.5-8mM

23
Q

Insulin actions [4]

A

Increase liver enzymes - synthesise glycogen
Increase adipocyte enzymes - synthesise TG

Inhibit lipolysis
Function as growth factors

24
Q

Phosphate pentose pathway

A

Cystolic pathway

Branch from G6P

25
Q

Increase G6P inhibits

A

Hexokinase -> prevent glucose phosphorylation

26
Q

Glucagon and adrenaline

A

Activate glycogen breakdown and inhibit CAMP PK

27
Q

Irreversible steps

A

G6Pase, F16BPase, pyruvate carboxylase and PEP carboxykinase

28
Q

Phosphorylation effect on PFK2 and F26BPase

A

Inhibit PFK2 and stim F26BPase

29
Q

Increase FA = Increase A CoA

A

Activate pyruvate carboxylase and inhibit pyruvate dehydrogenase

30
Q

Increase Glucagon

A

Inhibit PFK2 and slim F26BPase

31
Q

Decrease F26BP

A

Decrease PFK1 and relieve F16Pase inhibition

32
Q

Catecholamine actions [3]

A

Stim glucogen breakdown
BV compressed
Breakdown phosphocreatine

33
Q

Type 1 Diabetes causes

A

Autoimmune B cell destruction

`viral infection

34
Q

Type II Diabetes [3]

A

Impaired insulin secretion (amyloid deposit = less B cell mass)

Increased peripheral resistance (increase FA)

Increased hepatic glucose output

35
Q

Type II diabetes drugs

A

Sulphonylureas (Gliclazide)
Metformin
Thiazolidinedione

36
Q

Sulphonylureas

A

Glucose depolarise membrane & ATP-dependent K+ channel closing = Ca2+ influx = insulin secretion

37
Q

Metformin

A

No hypoglycaemia & suppress appetite

Increased insulin insensitivity

38
Q

Thiazolidinedione

A

Reduce hepatic glucose output
Increase muscle uptake
Enhance insulin effectiveness
Bind to nuclear receptor (peroxisome proliferator activated receptor)

39
Q

Hypoglycaemia

A

Below 4mM (2.5mM = unconscious)

Hypernatraemia
Hypovolaemia
Alcohol Pathologies - Adrenal Insufficiency